{"id":"https://openalex.org/W2397328669","doi":"https://doi.org/10.1158/2326-6074.cricimteatiaacr15-ia45","title":"Abstract IA45: Prospect of a vaccine to prevent cancer in BRCA1-2 mutation carriers","display_name":"Abstract IA45: Prospect of a vaccine to prevent cancer in BRCA1-2 mutation carriers","publication_year":2016,"publication_date":"2016-01-01","ids":{"openalex":"https://openalex.org/W2397328669","doi":"https://doi.org/10.1158/2326-6074.cricimteatiaacr15-ia45","mag":"2397328669"},"language":"en","primary_location":{"id":"doi:10.1158/2326-6074.cricimteatiaacr15-ia45","doi":"https://doi.org/10.1158/2326-6074.cricimteatiaacr15-ia45","is_oa":false,"landing_page_url":"https://doi.org/10.1158/2326-6074.cricimteatiaacr15-ia45","pdf_url":null,"source":{"id":"https://openalex.org/S2765010658","display_name":"Cancer Immunology Research","issn_l":"2326-6066","issn":["2326-6066","2326-6074"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Immunology Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040750947","display_name":"Robert H. Vonderheide","orcid":"https://orcid.org/0000-0002-7252-954X","observed_orcids":["https://orcid.org/0000-0002-7252-954X"]},"institutions":[{"id":"https://openalex.org/I4390039297","display_name":"Abramson Cancer Center","ror":"https://ror.org/01hvpjq66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392","https://openalex.org/I4390039297"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Robert H. Vonderheide","raw_affiliation_strings":["Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA","institution_ids":["https://openalex.org/I4390039297","https://openalex.org/I79576946"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5040750947"],"corresponding_institution_ids":["https://openalex.org/I4390039297","https://openalex.org/I79576946"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"4","issue":"1_Supplement","first_page":"IA45","last_page":"IA45"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brca1-2-mutation-carriers","display_name":"BRCA1/2 mutation carriers","score":0.925000011920929},{"id":"https://openalex.org/keywords/htert","display_name":"hTERT","score":0.7699999809265137},{"id":"https://openalex.org/keywords/tert","display_name":"telomerase reverse transcriptase","score":0.9570000171661377},{"id":"https://openalex.org/keywords/dna-vaccine","display_name":"DNA vaccine","score":0.8650000095367432},{"id":"https://openalex.org/keywords/cancer-immunoprevention","display_name":"cancer immunoprevention","score":0.621999979019165},{"id":"https://openalex.org/keywords/tumor-antigens","display_name":"tumor antigens","score":0.35100001096725464},{"id":"https://openalex.org/keywords/immune-evasion","display_name":"immune evasion","score":0.49799999594688416},{"id":"https://openalex.org/keywords/high-risk-cancer-patients","display_name":"high-risk cancer patients","score":0.5339999794960022},{"id":"https://openalex.org/keywords/tumor-cell-lysis","display_name":"tumor cell lysis","score":0.42899999022483826}],"concepts":[{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.6198895573616028},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.6172339916229248},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5512460470199585},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.5469189286231995},{"id":"https://openalex.org/C94581717","wikidata":"https://www.wikidata.org/wiki/Q331839","display_name":"Telomerase","level":3,"score":0.5247847437858582},{"id":"https://openalex.org/C2778378633","wikidata":"https://www.wikidata.org/wiki/Q2378309","display_name":"Cancer vaccine","level":4,"score":0.5149222612380981},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.477812796831131},{"id":"https://openalex.org/C125593758","wikidata":"https://www.wikidata.org/wiki/Q15315135","display_name":"Telomerase reverse transcriptase","level":4,"score":0.4657287001609802},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.4515114426612854},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4134068489074707},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.38508352637290955},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.31401583552360535},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.09723600745201111},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.09721013903617859},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.09670984745025635},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/2326-6074.cricimteatiaacr15-ia45","doi":"https://doi.org/10.1158/2326-6074.cricimteatiaacr15-ia45","is_oa":false,"landing_page_url":"https://doi.org/10.1158/2326-6074.cricimteatiaacr15-ia45","pdf_url":null,"source":{"id":"https://openalex.org/S2765010658","display_name":"Cancer Immunology Research","issn_l":"2326-6066","issn":["2326-6066","2326-6074"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Immunology Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2403213668","https://openalex.org/W7118005564","https://openalex.org/W2161254021","https://openalex.org/W1970555729","https://openalex.org/W1576481046","https://openalex.org/W2154551867","https://openalex.org/W2133301992","https://openalex.org/W2297394254","https://openalex.org/W2274764234","https://openalex.org/W2171987466"],"abstract_inverted_index":{"Abstract":[0],"New,":[1],"effective":[2],"immune":[3,15,29,77,210,288,298,363],"approaches":[4,30],"to":[5,26,31,49,75,112,141,171,206,365,434],"treat":[6],"cancer":[7,45,66,156,270,405,436],"not":[8,256],"only":[9],"underscore":[10],"the":[11,14,18,143,162,201,207,267,283,310,322,445],"power":[12],"of":[13,65,165,200,209,229,269,279,285,304,312,324,376,397,404,431,444],"system":[16],"in":[17,68,79,90,107,110,120,133,177,239,241,266,282,314,342,357,406,437],"therapeutic":[19],"setting,":[20],"but":[21],"also":[22,401],"spark":[23],"renewed":[24],"efforts":[25],"develop":[27],"specific":[28,230],"prevent":[32,402,435],"cancer.":[33,61,87],"We":[34],"are":[35,216,255],"focused":[36],"on":[37,222],"developing":[38,86],"a":[39,56,126,135,149,198,415,432],"novel":[40,416],"vaccine":[41,58,138,433],"that":[42,100,185,390],"prevents":[43],"BRCA1/2-related":[44,60],"when":[46],"administered":[47],"prophylactically":[48],"healthy":[50],"individuals":[51,80],"who":[52,360,371],"carry":[53],"BRCA1/2":[54,69,172],"mutations":[55],"polio":[57],"for":[59,85,94,155,247,275],"An":[62],"increasing":[63],"understanding":[64],"risk":[67,84],"mutation":[70,439],"carriers":[71],"provides":[72],"an":[73,242,362],"opportunity":[74],"test":[76],"prevention":[78,92],"at":[81],"extremely":[82],"high":[83],"It":[88],"is":[89,97,130,139,159,180,264,273,354,391,419],"this":[91],"setting":[93],"which":[95,115,134],"it":[96],"now":[98],"hypothesized":[99],"vaccines":[101,114,308],"will":[102,422],"work":[103],"(as":[104],"they":[105],"do":[106,117],"infectious":[108],"diseases)":[109],"contrast":[111],"post-exposure":[113],"generally":[116],"not,":[118],"especially":[119],"cancer-bearing":[121],"individuals.":[122],"In":[123,316,383],"initial":[124],"efforts,":[125],"first-in-human":[127],"clinical":[128,412],"trial":[129,413],"being":[131,197],"conducting":[132],"next-generation":[136],"DNA":[137,389,417],"used":[140],"target":[142],"telomerase":[144,175],"reverse":[145],"transcriptase":[146],"hTERT":[147,263,280,366],"as":[148],"potential":[150],"universal":[151],"tumor":[152,237,277,295,349],"antigen":[153],"exploitable":[154],"prevention.":[157],"Telomerase":[158],"expressed":[160],"by":[161,190,219,258,300],"vast":[163],"majority":[164],"human":[166,191,202],"cancers":[167],"including":[168,344],"those":[169,358],"related":[170],"mutation,":[173],"whereas":[174],"expression":[176,281],"normal":[178,251],"tissue":[179],"restricted.":[181],"Extensive":[182],"data":[183],"demonstrate":[184,309],"TERT":[186,215,235,259,313,377,388],"can":[187,225,394],"be":[188,291,423],"recognized":[189],"cytotoxic":[192],"T":[193,260,286,326,337],"lymphocytes":[194],"(CTLs)":[195],"despite":[196],"product":[199],"genome":[203],"potentially":[204],"subject":[205],"forces":[208],"tolerance.":[211],"Peptides":[212],"derived":[213],"from":[214],"naturally":[217],"processed":[218],"tumors,":[220],"presented":[221],"MHC,":[223],"and":[224,272,306,330,348,400,421],"trigger":[226],"effector":[227,340],"functions":[228,341],"CTLs.":[231],"TERT-specific":[232],"CTLs":[233],"lyse":[234],"positive":[236],"cells":[238,254,271,327,338],"vitro":[240,343],"antigen-specific,":[243],"MHC-restricted":[244],"fashion;":[245],"except":[246],"activated":[248],"B":[249],"cells,":[250],"hTERT+":[252],"MHC+":[253],"lysed":[257],"cells.":[261],"Because":[262],"involved":[265],"transformation":[268],"required":[274],"oncogenesis,":[276],"downregulation":[278],"face":[284],"cell":[287],"responses":[289],"may":[290],"incompatible":[292],"with":[293,369,386],"ongoing":[294],"growth,":[296],"addressing":[297],"escape":[299],"antigen-loss.":[301],"Clinical":[302],"studies":[303],"peptide-":[305],"cell-based":[307],"immunogenicity":[311],"patients.":[315],"multiple":[317],"studies,":[318],"we":[319],"have":[320,379],"observed":[321],"induction":[323],"hTERT-specific":[325,335],"both":[328],"systemically":[329],"intratumorally":[331],"after":[332],"peptide":[333,367],"vaccination.":[334],"CD8+":[336],"exhibit":[339],"proliferation,":[345],"IFN\u03b3":[346],"production,":[347],"lysis.":[350],"Median":[351],"overall":[352],"survival":[353],"significantly":[355],"longer":[356],"patients":[359,370],"achieved":[361],"response":[364],"compared":[368],"did":[372],"not.":[373],"Some":[374],"formulations":[375],"vaccination":[378],"been":[380],"immunologically":[381],"weak.":[382],"mice,":[384],"immunization":[385],"optimized":[387],"robustly":[392],"immunogenic":[393],"inhibit":[395],"growth":[396],"preexisting":[398],"tumors":[399],"formation":[403],"challenge":[407],"experiments":[408],"without":[409],"toxicity.":[410],"A":[411],"testing":[414],"formulation":[418],"underway":[420],"discussed.":[424],"Citation":[425],"Format:":[426],"Robert":[427],"H.":[428],"Vonderheide.":[429],"Prospect":[430],"BRCA1-2":[438],"carriers.":[440],"[abstract].":[441],"In:":[442],"Proceedings":[443],"CRI-CIMT-EATI-AACR":[446],"Inaugural":[447],"International":[448],"Cancer":[449,465],"Immunotherapy":[450],"Conference:":[451],"Translating":[452],"Science":[453],"into":[454],"Survival;":[455],"September":[456],"16-19,":[457],"2015;":[458],"New":[459],"York,":[460],"NY.":[461],"Philadelphia":[462],"(PA):":[463],"AACR;":[464],"Immunol":[466],"Res":[467],"2016;4(1":[468],"Suppl):Abstract":[469],"nr":[470],"IA45.":[471]},"counts_by_year":[],"updated_date":"2026-07-14T23:27:15.235271","created_date":"2016-06-24T00:00:00"}